{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T08:15:04Z","timestamp":1770538504084,"version":"3.49.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2019,4,25]],"date-time":"2019-04-25T00:00:00Z","timestamp":1556150400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100004351","name":"Sultan Qaboos University","doi-asserted-by":"publisher","award":["IG\/MED\/\/PHAR\/16\/02"],"award-info":[{"award-number":["IG\/MED\/\/PHAR\/16\/02"]}],"id":[{"id":"10.13039\/501100004351","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1007\/s00210-019-01655-w","type":"journal-article","created":{"date-parts":[[2019,4,25]],"date-time":"2019-04-25T11:05:06Z","timestamp":1556190306000},"page":"1005-1013","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Effect of tocilizumab, an interleukin-6 inhibitor, on early stage streptozotocin-induced diabetic nephropathy in rats"],"prefix":"10.1007","volume":"392","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7959-1784","authenticated-orcid":false,"given":"Aly M.","family":"Abdelrahman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yousuf","family":"Al Suleimani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asem","family":"Shalaby","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammed","family":"Ashique","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Priyadarsini","family":"Manoj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Badreldin H.","family":"Ali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,4,25]]},"reference":[{"key":"1655_CR1","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1007\/s12272-001-2155-5","volume":"31","author":"AM Abdelrahman","year":"2008","unstructured":"Abdelrahman AM, Al Suleimani YM (2008) Four-week administration of nimesulide, a cyclooxygenase-2 inhibitor, improves endothelial dysfunction in the hindlimb vasculature of streptozotocin-induced diabetic rats. Arch Pharm Res 31:1584\u20131589","journal-title":"Arch Pharm Res"},{"key":"1655_CR2","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.biopha.2018.05.118","volume":"105","author":"AM Abdelrahman","year":"2018","unstructured":"Abdelrahman AM, Al Suleimani YM, Ashique M, Manoj P, Ali BH (2018) Effect of infliximab and tocilizumab on fructose-induced hyperinsulinemia and hypertension in rats. Biomed Pharmacother 105:182\u2013186","journal-title":"Biomed Pharmacother"},{"key":"1655_CR3","doi-asserted-by":"publisher","first-page":"389","DOI":"10.5606\/ArchRheumatol.2018.6753","volume":"33","author":"IA Choi","year":"2018","unstructured":"Choi IA, Lee SJ, Park W, Park SH, Shim SC, Baek HJ, Yoo DH, Kim HA, Lee SK, Lee YJ, Park YE, Cha HS, Lee EY, Lee EB, Song YW (2018) Effects of tocilizumab therapy on serum interleukin-33 and interleukin-6 levels in patients with rheumatoid arthritis. Arch Rheumatol 33:389\u2013394","journal-title":"Arch Rheumatol"},{"key":"1655_CR4","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/j.semarthrit.2017.10.022","volume":"47","author":"C Diaz-Torne","year":"2018","unstructured":"Diaz-Torne C, Ortiz MDA, Moya P, Hernandez MV, Reina D, Castellvi I, De Agustin JJ, Fuente D, Corominas H, Sanmarti R, Zamora C, Cant\u00f3 E, Vidal S (2018) The combination of IL-6 and its soluble receptor is associated with the response of rheumatoid arthritis patients to tocilizumab. Semin Arthritis Rheum 47:757\u2013764","journal-title":"Semin Arthritis Rheum"},{"key":"1655_CR5","doi-asserted-by":"publisher","unstructured":"Fiseha T, Tamir Z. (2016) Urinary markers of tubular injury in early diabetic nephropathy. Int J Nephrol ID 4647685, 10 \n                    https:\/\/doi.org\/10.1155\/2016\/4647685","DOI":"10.1155\/2016\/4647685"},{"key":"1655_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000492825","volume":"26","author":"GE Fouli","year":"2018","unstructured":"Fouli GE, Gnudi L (2018) The future: experimental therapies for renal disease in diabetes. Nephron 26:1\u20135","journal-title":"Nephron"},{"key":"1655_CR7","doi-asserted-by":"publisher","first-page":"2378","DOI":"10.1159\/000486154","volume":"44","author":"B Hou","year":"2017","unstructured":"Hou B, Qiang G, Zhao Y, Yang X, Chen X, Yan Y, Wang X, Liu C, Zhang L, Du G (2017) Salvianolic acid a protects against diabetic nephropathy through ameliorating glomerular endothelial dysfunction via inhibiting AGE-RAGE signaling. Cell Physiol Biochem 44:2378\u20132394","journal-title":"Cell Physiol Biochem"},{"key":"1655_CR8","doi-asserted-by":"publisher","unstructured":"Hu X, Liu W, Yan Y, Liu H, Huang Q, Xiao Y, Gong Z, Du J (2018, 2018) Vitamin D protects against diabetic nephropathy: evidence-based effectiveness and mechanism. Eur J Pharmacol. \n                    https:\/\/doi.org\/10.1016\/j.ejphar.2018.09.037","DOI":"10.1016\/j.ejphar.2018.09.037"},{"key":"1655_CR9","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.biopha.2017.07.095","volume":"94","author":"K Jaikumkao","year":"2017","unstructured":"Jaikumkao K, Pongchaidecha A, Chatsudthipong V, Chattipakorn SC, Chattipakorn N, Lungkaphin A (2017) The roles of sodium-glucose cotransporter 2 inhibitors in preventing kidney injury in diabetes. Biomed Pharmacother 94:176\u2013187","journal-title":"Biomed Pharmacother"},{"key":"1655_CR10","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1093\/ndt\/gfu233","volume":"30","author":"SA Jones","year":"2015","unstructured":"Jones SA, Fraser DJ, Fielding CA, Jones GW (2015) Interleukin-6 in renal disease and therapy. Nephrol Dial Transplant 30:564\u2013574","journal-title":"Nephrol Dial Transplant"},{"key":"1655_CR11","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1007\/s00210-012-0794-3","volume":"385","author":"A Joshi","year":"2012","unstructured":"Joshi A, Woodman OL (2012) Increased nitric oxide activity compensates for increased oxidative stress to maintain endothelial function in rat aorta in early type 1 diabetes. Naunyn Schmiedeberg's Arch Pharmacol 385:1083\u20131094","journal-title":"Naunyn Schmiedeberg's Arch Pharmacol"},{"key":"1655_CR12","doi-asserted-by":"publisher","first-page":"e208","DOI":"10.1016\/j.wneu.2018.12.069","volume":"124","author":"Y Karatas","year":"2018","unstructured":"Karatas Y, Erdi MF, Kaya B, Keskin F, C\u00fcce G, K\u0131l\u0131nc I, Uyar M, Izci EK, Kalkan E (2018) Neuroprotective effects of tocilizumab on experimentally-induced spinal cord ischemia-reperfusion injury. World Neurosurg 124:e208\u2013e213. \n                    https:\/\/doi.org\/10.1016\/j.wneu.2018.12.069","journal-title":"World Neurosurg"},{"key":"1655_CR13","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s12272-015-0569-8","volume":"38","author":"GW Kim","year":"2015","unstructured":"Kim GW, Lee NR, Pi RH, Lim YS, Lee YM, Lee JM, Jeong HS, Chung SH (2015) IL-6 inhibitors for treatment of rheumatoid arthritis: past, present and future. Arch Pharm Res 38:575\u2013584","journal-title":"Arch Pharm Res"},{"key":"1655_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ijcard.2018.04.136","volume":"271","author":"O Kleveland","year":"2018","unstructured":"Kleveland O, Ueland T, Kunszt G, Bratlie M, Yndestad A, Broch K, Holte E, Ryan L, Amundsen BH, Bendz B, Aakhus S, Espevik T, Halvorsen B, Mollnes TE, Wiseth R, Gullestad L, Aukrust P, Dam\u00e5s JK (2018) Interleukin-6 receptor inhibition with tocilizumab induces a selective and substantial increase in plasma IP-10 and MIP-1\u03b2 in non-ST-elevation myocardial infarction. Int J Cardiol 271:1\u20137","journal-title":"Int J Cardiol"},{"key":"1655_CR15","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1002\/cre2.11","volume":"13","author":"T Kobayashi","year":"2015","unstructured":"Kobayashi T, Ito S, Kobayashi D, Kojima A, Shimada A, Narita I, Murasawa A, Nakazono K, Yoshie (2015) Interleukin-6 receptor inhibitor tocilizumab ameliorates periodontal inflammation in patients with rheumatoid arthritis and periodontitis as well as tumor necrosis factor inhibitors. Clin Exp Dent Res 13:63\u201373","journal-title":"Clin Exp Dent Res"},{"key":"1655_CR16","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1007\/s00125-010-2028-x","volume":"54","author":"R Kodera","year":"2011","unstructured":"Kodera R, Shikata K, Kataoka HU, Takatsuka T, Miyamoto S, Sasaki M, Kajitani N, Nishishita S, Sarai K, Hirota D, Sato C, Ogawa D, Makino H, Matavelli LC, Zatz R, Siragy HM (2011) Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes. Diabetologia 54:965\u2013978","journal-title":"Diabetologia"},{"key":"1655_CR17","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1016\/j.bbrc.2013.12.049","volume":"443","author":"R Kodera","year":"2014","unstructured":"Kodera R, Shikata K, Takatsuka T, Oda K, Miyamoto S, Kajitani N, Hirota D, Ono T, Usui HK, Makino H (2014) Dipeptidyl peptidase-4 inhibitor ameliorates early renal injury through its anti-inflammatory action in a rat model of type 1 diabetes. Biochem Biophys Res Commun 443:828\u2013833","journal-title":"Biochem Biophys Res Commun"},{"key":"1655_CR18","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s00592-007-0007-6","volume":"44","author":"Y Moriwaki","year":"2007","unstructured":"Moriwaki Y, Inokuchi T, Yamamoto A, Ka T, Tsutsumi Z, Takahashi S, Yamamoto T (2007) Effect of TNF-a inhibition on urinary albumin excretion in experimental diabetic rats. Acta Diabetol 44:215\u2013218","journal-title":"Acta Diabetol"},{"key":"1655_CR19","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1681\/ASN.2007070744","volume":"19","author":"Y Nechemia-Arbely","year":"2008","unstructured":"Nechemia-Arbely Y, Barkan D, Pizov G, Shriki A, Rose-John S, Galun E, Axelrod JH (2008) IL-6\/IL-6R axis plays a critical role in acute kidney injury. J Am Soc Nephrol 19:1106\u20131115","journal-title":"J Am Soc Nephrol"},{"key":"1655_CR20","doi-asserted-by":"publisher","first-page":"3959","DOI":"10.1182\/blood-2008-05-155846","volume":"112","author":"N Nishimoto","year":"2008","unstructured":"Nishimoto N, Terao K, Mima T, Nakahara H, Takagi N, Kakehi T (2008) Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood 112:3959\u20133564","journal-title":"Blood"},{"key":"1655_CR21","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1681\/ASN.2008050503","volume":"20","author":"LM Russo","year":"2009","unstructured":"Russo LM, Sandoval RM, Campos SB, Molitoris BA, Comper WD, Brown D (2009) Impaired tubular uptake explains albuminuria in early diabetic nephropathy. J Am Soc Nephrol 20:489\u2013494","journal-title":"J Am Soc Nephrol"},{"key":"1655_CR22","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.1080\/21645515.2017.1316909","volume":"13","author":"M Sheppard","year":"2017","unstructured":"Sheppard M, Laskou F, Stapleton PP, Hadavi S, Dasgupta B (2017) Tocilizumab (Actemra). Hum Vaccin Immunother 13:1972\u20131988","journal-title":"Hum Vaccin Immunother"},{"key":"1655_CR23","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1159\/000045634","volume":"85","author":"M Shikano","year":"2000","unstructured":"Shikano M, Sobajima H, Yoshikawa H, Toba T, Kushimoto H, Katsumata H, Tomita M, Kawashima S (2000) Usefulness of a highly sensitive urinary and serum IL-6 assay in patients with diabetic nephropathy. Nephron 85:81\u201385","journal-title":"Nephron"},{"key":"1655_CR24","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1111\/j.1523-1755.2004.00512.x","volume":"65","author":"EM Simmons","year":"2004","unstructured":"Simmons EM, Himmelfarb J, Sezer MT, Chertow GM, Mehta RL, Paganini EP, Soroko S, Freedman S, Becker K, Spratt D, Shyr Y, Ikizler TA, PICARD Study Group (2004) Plasma cytokine levels predict mortality in patients with acute renal failure. Kidney Int 65:1357\u20131365","journal-title":"Kidney Int"},{"key":"1655_CR25","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.2337\/diab.44.10.1233","volume":"44","author":"D Suzuki","year":"1995","unstructured":"Suzuki D, Miyazaki M, Naka R, Koji T, Yagame M, Jinde K, Endoh M, Nomoto Y, Sakai H (1995) In situ hybridization of interleukin 6 in diabetic nephropathy. Diabetes 44:1233\u20131238","journal-title":"Diabetes"},{"key":"1655_CR26","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1007\/s40620-014-0136-2","volume":"28","author":"P Tessari","year":"2015","unstructured":"Tessari P (2015) Nitric oxide in the normal kidney and in patients with diabetic nephropathy. J Nephrol 28:257\u2013268","journal-title":"J Nephrol"},{"key":"1655_CR27","first-page":"2784","volume":"41","author":"D Wang","year":"2018","unstructured":"Wang D, Zhang G, Chen X, Wei T, Liu C, Chen C, Gong Y, Wei Q (2018) Sitagliptin ameliorates diabetic nephropathy by blocking TGF-\u03b21\/Smad signaling pathway. Int J Mol Med 41:2784\u20132792","journal-title":"Int J Mol Med"},{"key":"1655_CR28","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.metabol.2018.01.002","volume":"83","author":"R Wu","year":"2018","unstructured":"Wu R, Liu X, Yin J, Wu H, Cai X, Wang N, Qian Y, Wang F (2018) IL-6 receptor blockade ameliorates diabetic nephropathy via inhibiting inflammasome in mice. Metabolism 83:18\u201324","journal-title":"Metabolism"},{"key":"1655_CR29","doi-asserted-by":"publisher","unstructured":"Yang J, Chen J, Yan J, Zhang L, Chen G, He L, Wang Y (2012) Effect of interleukin 6 deficiency on renal interstitial fibrosis. PLos ONE 7(12):e52415. \n                    https:\/\/doi.org\/10.1371\/journal.pone.0052415","DOI":"10.1371\/journal.pone.0052415"},{"key":"1655_CR30","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1161\/HYPERTENSIONAHA.111.173328","volume":"59","author":"W Zhang","year":"2012","unstructured":"Zhang W, Wang W, Yu H, Zhang Y, Dai Y, Ning C, Tao L, Sun H, Kellems RE, Blackburn MR, Xia Y (2012) Interleukin 6 underlies angiotensin II-induced hypertension and chronic renal damage. Hypertension. 59:136\u2013144","journal-title":"Hypertension."}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-019-01655-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00210-019-01655-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-019-01655-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,23]],"date-time":"2020-04-23T23:11:32Z","timestamp":1587683492000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00210-019-01655-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,25]]},"references-count":30,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["1655"],"URL":"https:\/\/doi.org\/10.1007\/s00210-019-01655-w","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,25]]},"assertion":[{"value":"6 February 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All experimental designs were approved by the Medical Research Committee, College of Medicine and Health Sciences, Sultan Qaboos University. All procedures involving animals and their care were carried out in accordance with the guidelines of the Animal Ethical Committee of Sultan Qaboos University and international laws and policies (EEC Council directives 2010\/63\/EU, 22 September, 2010 and NIH Guide for the Care and Use of Laboratory Animals, NIH Publications, 8th edition, 2011).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All applicable international, national, and\/or institutional guidelines for the care and use of animals were followed.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}